Nutritional Status of Children with Pediatric Acute Lymphoblastic Leukemia

2021 ◽  
Vol 15 (12) ◽  
pp. 3222-3224
Author(s):  
Wasila Shamim ◽  
Saadia Anwar ◽  
Mahwish Faizan
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Nutritional Status ◽  
Lymphoblastic Leukemia ◽  
Older Age ◽  
Age Group ◽  
Pediatric Acute Lymphoblastic Leukemia ◽  
Significant Difference ◽  
Nutritional Status Of Children ◽  
Height For Age ◽  
Weight For Age

Aim: To analyze the nutritional status of children with pediatric Acute Lymphoblastic Leukemia (ALL) at presentation. Study design: Descriptive prospective study Place and duration of study: Department of Paediatric Haematology Oncology, Children Hospital, Lahore from March 2018 to April 2019. Methodology: A total of 195 children diagnosed as acute lymphoblastic leukemia on bone marrow biopsy were included. Anthropometric measurements were taken for each patient. Results: Out of 195 diagnosed patients with ALL, majority were having B-cell ALL 165(84.6%) and 30(15.4%) T-cell ALL. There was almost equal number of both standard and high risk patients (49% vs 51%) respectively. Mean age of children was 6.79±3.78 years and there was male predominance 120(61.5%). The percentage of children having weight for age <5th centile was 91(47), only 8(4%) were overweight or obese. Children under the age of five years had a slightly higher propensity of weight <5th centile i.e. 47(51.6%) as compared to older age group 5-10 years 26(28.7%) and >10 years 18(19.7%) (p=0.295).Similarly height for age was <5th centile in 50(26%) children in total, and in under 5 year age group 26(13.3%) but there was no statistically significant difference related to age above 5 years (p=0.547). Conclusion: Pediatric ALL has overall high prevalence of under nutrition and both weight for age and height for age is lower in under-five children as compared to older age group. Keywords: Children, cancer, nutrition, malnutrition, Acute Lymphoblastic leukemia

scholarly journals Differences between WHO Growth Standards and China Growth Standards in Assessing the Nutritional Status of Children Aged 0–36 Months Old

2019 ◽  
Vol 17 (1) ◽  
pp. 251
Author(s):  
Qianling Tian ◽  
Xiao Gao ◽  
Tingting Sha ◽  
Qiong He ◽  
Gang Cheng ◽  
...  
Keyword(s):  
Nutritional Status ◽  
World Health ◽  
Growth Standards ◽  
The World ◽  
Z Scores ◽  
Nutritional Status Of Children ◽  
Height For Age ◽  
Weight For Age ◽  
China’S Growth

Background: At present, whether to use the World Health Organization’s (WHO) growth standards or native growth standards to assess the nutritional status in a given population is unclear. This study aimed to compare the differences between the WHO’s growth standards and China’s growth standards in assessing the nutritional status of children aged 0~36 months. Methods: We used z-scores to evaluate the nutritional status of children. The weight-for-age z-scores (WAZs), length/height-for-age z-scores (LAZ/HAZs), and weight-for-length/height z-scores (WLZ/WHZs) were calculated using the WHO’s growth standards and China’s growth standards. MeNemar’s test was used to compare the nutritional status of children. Results: The results in this study showed that there were differences between the WHO’s standards and China’s standards in assessing children’s nutritional status except for stunting and obesity. The prevalence of underweight assessed using China’s standards was higher than when using the WHO’s standards (except when 3 and 36 months old). The prevalence of wasting was significantly higher when assessed using China’s standards than when using the WHO’s standards from 12 to 36 months. The prevalence of overweight was higher when assessed using the WHO’s standards from 3 to 8 months. Conclusions: Both the WHO’s and China’s growth standards are useful measures in assessing children’s nutritional status but with key significant differences. Therefore, caution should be taken in selecting appropriate measures in a given population.

scholarly journals Pengaruh Intervensi Makanan Tambahan Padat Energi dan Protein Berbasis Pangan Lokal terhadap Perbaikan Status Gizi Balita

2020 ◽  
Vol 2 (1) ◽  
pp. 26-33
Author(s):  
Utma Aspatria
Keyword(s):  
Nutritional Status ◽  
Children Under Five ◽  
Under Five ◽  
Low Protein ◽  
Randomized Design ◽  
Intervention Treatment ◽  
Nutritional Status Of Children ◽  
Energy Dense Food ◽  
Height For Age ◽  
Weight For Age

Malnutrition problems that mostly occur in NTT are particularly caused by low protein intake. Therefore, this study was designed to intervene in feeding energy and protein dense snack to improve the nutritional status of children under five. This research was conducted in Tanah Putih Village, Kupang Tengah Sub-district, Kupang District. The research was an experimental method with a completely randomized design. Three types of intervention were given, namely: p1 = cassava + skipjack fish; p2 = cassava + rice beans; and p3 = cassava + skipjack fish + rice beans. Each sample consumed energy and protein dense snacks (according to treatment) for 30 days of trial. The results showed that the majority of children had a higher acceptance level for the intervention (88,9%). The results also showed that the provision of energy-dense food and protein significantly (p <0.05) improved the nutritional status of children under five, with weight for height indicator. However, the intervention had no significant effect (p> 0.05) with the indicator of height for age. The results of the analysis of variance showed a significant nutritional status improvement for the composition of cassava and fish (P1) (p <0.05) using the indicators wight for height and weight for age. Yet, it had not significantly contributed to improving the nutritional status of children under five using the height for age indicator.Advanced analysis using the Duncan test showed that the intervention treatment with the composition of cassava and rice beans had the strongest effect on improving the nutritional status of children under five. Keynote: Intervention, Malnutrition, Suplementary Food.

Pharmacogenetic Outcomes of Pediatric Acute Lymphoblastic Leukemia in Korea

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5047-5047
Author(s):  
Hyoung Jin Kang ◽  
Hyery Kim ◽  
Young Jin Seo ◽  
Mi Kyung Jang ◽  
Yongtaek Oh ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Genetic Polymorphism ◽  
Lymphoblastic Leukemia ◽  
Individualized Therapy ◽  
Treatment Result ◽  
Mutant Type ◽  
Term Survival ◽  
Pediatric Acute Lymphoblastic Leukemia ◽  
Korean Patients ◽  
Significant Difference

Abstract Treatment result of pediatric acute lymphoblastic leukemia (ALL) has been markedly improved, but treatment related toxicities and relapse are still remaining problems. Genetic polymorphism is an important factor in the effectiveness and toxicity of anti-leukemic drugs and pharmacogenetics are beginning to emerge as useful research filed to solve those problems. In our experience in the treatment of ALL, many Korean patients could not tolerate full dosages of Western protocols. To make basis for individualized therapy with pharmacogenetics, we analyzed major genes implicated in the treatment of ALL. Fourteen genes of total 103 patients with ALL were analyzed with TotalPlex gene amplification methods (Mol Cell Probes.2008. 22: 193). Among the drug related genes (percentage of mutant type) including CYP3A4*1B (0%), CYP3A5*3 (0%), GSTP1 (22.3%), GSTM1 (20.4%), GSTT1 (16.5%), MDR1 exon 21 (76.3%), MDR1 exon 26 (61.2%), MTHFR (64.1%), MTHFR 1298 (29.1%), NR3C1 1088 (0%), RFC 80 (79.6%), TPMT combined genotype (7%), VDR intron 8 (10.7%), VDR FokI (67%), incidence of mutant was higher in GSTM1 deletion, lower in MTHFR 1298, TYMS enhancer repeat, and VDR intron 8 comparing with the data of Western whites (Rocha J.C. et al. Blood 2005). As we had modified the dose of anti-leukemic agents depending on the toxicity during the treatment, we analyzed the relationship between the dose percent of actually administered dose and the distribution of each mutant to find out polymorphisms affecting toxicities of chemotherapeutic drugs. The mean dose percent of mercaptopurine was lower in patients with variant TPMT then those with wild type (33.2% vs. 53.5%, P=0.04), but there was no polymorphism that influenced the dose percent of methotrexate, daunorubicin, doxorubicin, and L-asparaginase. There was no significant difference in the incidence of genotypes between risk groups and individual mutant did not affect long term survival and relapse in Korean patients with ALL. In conclusion, we found some difference in the incidence of mutant genotypes related to the pharmacogenetics of ALL between Korean and Western whites, but there was no individual genetic polymorphism that affect on the treatment outcome. We expect more extensive researches about pharmacogenetics of Korean to establish the basis for individualized therapy with the consideration of ethnical difference.

scholarly journals Nutritional status of children with acute lymphoblastic leukemia: a longitudinal study

1997 ◽  
Vol 65 (1) ◽  
pp. 95-100 ◽  
Author(s):  
L Delbecque-Boussard ◽  
F Gottrand ◽  
S Ategbo ◽  
B Nelken ◽  
F Mazingue ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Acute Lymphoblastic Leukemia ◽  
Nutritional Status ◽  
Lymphoblastic Leukemia ◽  
Nutritional Status Of Children

scholarly journals Nutritional status of children during treatment for acute lymphoblastic leukemia in Guatemala

2012 ◽  
Vol 60 (6) ◽  
pp. 911-915 ◽  
Author(s):  
Federico Antillon ◽  
Emanuela Rossi ◽  
Ana Lucia Molina ◽  
Alessandra Sala ◽  
Paul Pencharz ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Nutritional Status ◽  
Lymphoblastic Leukemia ◽  
Nutritional Status Of Children

Biologic Features and Treatment Outcome of Secondary Acute Lymphoblastic Leukemia - Review of 101 Cases.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4345-4345
Author(s):  
Ranga Shivakumar ◽  
Wei Tan ◽  
Gregory Wilding ◽  
Eunice S. Wang ◽  
Meir Wetzler
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Age Groups ◽  
Primary Diagnosis ◽  
Initial Diagnosis ◽  
Older Age ◽  
Time Interval ◽  
Age Group ◽  
Complex Karyotype ◽  
Old Patients

Abstract Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well described. Data suggested that sALL occurs more frequently at older age. Since leukemia at older age in general is associated with worse outcome, we wanted to assess the biology and outcome of patients with sALL by age at time of primary diagnosis. We describe a cohort of 7 patients and found additional 94 cases in the literature on whom biological parameters were described. Patients were stratified (at least 5 patients per strata) according to their age at initial diagnosis (<18, 18–59, and ≥60 years of age), initial diagnosis [acute myeloid leukemia (AML), Hodgkin’s disease (HD), neuroblastoma, breast and prostate cancers], cytogenetic groups [diploid, t(9;22), 11q23 aberrations, complex karyotype], immunophenotypes (B vs. T), and Burkitt’s defined by either morphology and/or cytogenetic analysis demonstrating c-myc rearrangement. A total of 101 patients were evaluated; 29 were <18, 54 were 18–59 and 18 were ≥60 years old. The distribution of primary diagnoses was as expected: neuroblastoma was seen only in the <18 age group (P=0.003), HD was more common in the 18–59 age group (75% of all HD cases; P=0.084) while breast (P=0.003) and prostate (P=0.005) cancers were prevalent only in the >18 year old patients. The time interval to develop sALL was similar among the three age groups (3, 2.2 and 1.8 years, P=0.561). However, the time interval to develop sALL was longer for HD (5.5 years) and neuroblastoma (3.7 years) as compared to AML (1 year), breast (1.6 years) and prostate (1.98 years) cancers (overall P=0.0003). Further, the time interval to develop sALL was significantly longer for patients with complex karyotype (5.3 years) as compared to all other aberrations [11q23 − 1.78; t(9;22) − 1.9; diploid − 1.98 years; overall P=0.0497]. Disease characteristics at diagnosis were as follows: T cell immunophenotype was more common in the <18 age group (P=0.016) and the presence of 11q23, t(9;22), complex and normal karyotypes was equally distributed among the three age groups (P=0.2, 0.073, 0.635 and 0.271 individually). Complete remission was infrequent in the ≥60 age group (22.22%) compared to the other groups (73.9% for <18 and 67.7% for 18–59; P=0.025). Even though only patients <60 years old were transplanted (33.3% for <18 and 19.4% for 18–59; P=0.102), the overall survival was poor in all age groups [probability of survival at 1 year for <18=0.222, 18–59=0.226 and ≥60=0.3 (P=0.7941)]. Primary diagnoses, cytogenetic subgroups and immunophenotype did not affect outcome. In summary, the time interval to develop sALL is significantly longer for HD, neuroblastoma and complex karyotype. However, sALL is associated with very poor outcome regardless of age and any of the biologic features. Therefore, identification of prognostic factors to prevent the occurrence of sALL is needed.

Sign in / Sign up

Export Citation Format

Share Document